Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 13/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.84 |
| ▸ | HTR1A | P08908 | 8/20 | 0.47 |
| ▸ | HTR1D | P28221 | 8/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246330 | 0.95 | HTR1B (0.93) | HTR1BKCNH2HTR1AHTR1DNFKB1 | |
| SCHEMBL4247675 | 0.91 | HTR1B (1.00) | HTR1BKCNH2HTR1AHTR1DNFKB1 | |
| SCHEMBL4247047 | 0.91 | HTR1B (1.00) | HTR1BKCNH2HTR1AHTR1DNFKB1 | |
| SCHEMBL4246216 | 0.91 | HTR1B (0.80) | HTR1BKCNH2HTR1AHTR1DNFKB1 | |
| SCHEMBL4246743 | 0.91 | HTR1B (0.80) | HTR1BKCNH2HTR1AHTR1DNFKB1 | |
| SCHEMBL4246714 | 0.89 | HTR1B (0.83) | HTR1BKCNH2HTR1AHTR1DNFKB1 | |
| SCHEMBL4252027 | 0.88 | HTR1B (0.81) | HTR1BKCNH2HTR1AHTR1DNFKB1 | |
| SCHEMBL4247598 | 0.88 | HTR1B (0.65) | HTR1BKCNH2HTR1AHTR1DNPC1 | |
| SCHEMBL4575917 | 0.88 | HTR1B (0.80) | HTR1BKCNH2HTR1AHTR1DNFKB1 | |
| SCHEMBL4575764 | 0.87 | HTR1B (0.86) | HTR1BKCNH2HTR1AHTR1DNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945624-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | Astra Zeneca AB (SE) | 2008-07-23 | — | — | EP | claimed |
| US-20070185107-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | claimed |
| WO-2007053095-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20090170851-A1 | Chroman Compounds | BERNSTEIN PETER | 2009-07-02 | — | — | US | disclosed |
| US-20090170851-A1 | Chroman Compounds | BERNSTEIN PETER | 2009-07-02 | — | — | US | disclosed |
| US-20090170851-A1 | Chroman Compounds | BERNSTEIN PETER | 2009-07-02 | — | — | US | disclosed |
| EP-1945624-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | Astra Zeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| US-20070185107-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185107-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185107-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| WO-2007053095-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053095-A1 | CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170851-A1 | Chroman Compounds | CYP3A43, CYP2C9, CYP2C8 | HTR1B 611/4885KCNH2 1085/4885HTR1A 167/4885 |
| US-20070185107-A1 | Chroman compounds | CYP3A43, CYP2C9, CYP2C8 | HTR1B 611/4885KCNH2 1085/4885HTR1A 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.